Using a panel of four human AML cell lines (MOLM14, MV411, MonoMac6, HL60), we established the single-agent anti-leukemic activity of the BCL-2 inhibitor S55746, the MCL-1 inhibitor S63845, and CalPegA. This evidence concerns the gene BCL2 and acute myeloid leukemia.